Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eureka Therapeutics Starts US Trial of Liver Cancer T-Cell Therapy

publication date: Aug 5, 2019

Eureka Therapeutics, a Bay Area immunotherapy company, began a US Phase I/II clinical trial of its liver cancer T-Cell therapy at the City of Hope Hospital in Los Angeles. Last year, the candidate completed a small proof-of-concept trial among heavily pre-treated liver cancer patients in China that showed early signs of efficacy. ET140202 ARTEMIS™ includes a propriety antibody that attaches to a protein unique to liver cancer and also features a re-engineered T-Cell that greatly reduces the cytokine release syndrome that plagues most other T-Cell therapies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here